바이러스 벡터 및 플라스미드 DNA 제조 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Viral Vector & Plasmid DNA Manufacturing Market size is expected to reach USD 46.95 Billion in 2034 from USD 8.50 Billion (2025) growing at a CAGR of 20.92% during 2026-2034.

The Global Viral Vector & Plasmid DNA Manufacturing Market has witnessed rapid expansion driven by the growing adoption of gene therapies, cell therapies, and advanced biologics. Viral vectors such as lentivirus and adenovirus are essential for delivering genetic material in gene editing and immunotherapy applications. The surge in clinical trials for CAR-T therapies and rare disease treatments has significantly increased demand for high-quality vector and plasmid DNA production capabilities.

Key growth drivers include rising investment in biotechnology research, increasing regulatory approvals for gene-based therapies, and expanding partnerships between biotech firms and contract development and manufacturing organizations (CDMOs). Technological advancements in scalable manufacturing platforms and improved purification techniques have enhanced production efficiency. Governments and private investors are also funding infrastructure development to address supply constraints and accelerate commercialization.

Looking ahead, the market is poised for strong growth as gene therapy pipelines continue to expand globally. The transition from small-scale clinical manufacturing to large-scale commercial production will create significant opportunities. Innovations in suspension cell culture systems, automation, and closed manufacturing processes are expected to improve yields and reduce costs, supporting long-term expansion of the viral vector and plasmid DNA manufacturing industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vector Type

• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End-use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific, Merck KGaA, Lonza, Fujifilm Diosynth Biotechnologies, Catalent Inc, Wuxi Biologics, Cobra Biologics, Takara Bio Inc, BioMarin Pharmaceutical, RegenxBio, Inc, Miltenyi Biotec GmbH, Sirion Biotech GmbH, Batavia Biosciences, Waisman Biomanufacturing, Genezen Laboratories

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Vector Type
• 4.2. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Retrovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Adeno-Associated Virus (AAV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Lentivirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Plasmids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. Upstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Downstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Antisense & RNAi Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Research Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY DISEASE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Disease
• 8.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Vector Type
  • 9.2.2 By Workflow
  • 9.2.3 By Application
  • 9.2.4 By End-use
  • 9.2.5 By Disease
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Vector Type
  • 9.3.2 By Workflow
  • 9.3.3 By Application
  • 9.3.4 By End-use
  • 9.3.5 By Disease
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Vector Type
  • 9.4.2 By Workflow
  • 9.4.3 By Application
  • 9.4.4 By End-use
  • 9.4.5 By Disease
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Vector Type
  • 9.5.2 By Workflow
  • 9.5.3 By Application
  • 9.5.4 By End-use
  • 9.5.5 By Disease
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Vector Type
  • 9.6.2 By Workflow
  • 9.6.3 By Application
  • 9.6.4 By End-use
  • 9.6.5 By Disease
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Thermo Fisher Scientific
  • 11.2.2 Merck KGaA
  • 11.2.3 Lonza
  • 11.2.4 Fujifilm Diosynth Biotechnologies
  • 11.2.5 Catalent Inc
  • 11.2.6 Wuxi Biologics
  • 11.2.7 Cobra Biologics
  • 11.2.8 Takara Bio Inc
  • 11.2.9 BioMarin Pharmaceutical
  • 11.2.10 RegenxBioInc
  • 11.2.11 Miltenyi Biotec GmbH
  • 11.2.12 Sirion Biotech GmbH
  • 11.2.13 Batavia Biosciences
  • 11.2.14 Waisman Biomanufacturing
  • 11.2.15 Genezen Laboratories